Skip to content

Braveheart Bio

US · BRVE #2845 by market cap Listed 2026
18.58 -1.21 -6.11%
Live - 5344 symbols - heartbeat 499s ago · 2026-10-08 07:00
Pre-market 18.58 0.00%
After-hours 18.58 0.00%
Market cap
1.67B
P/B
-17.45
EPS
-0.94
Reader sentiment Are you bullish or bearish on BRVE?

Anonymous reader poll. Unscientific, not investment advice.

About Braveheart Bio

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

CEO
Dr. Travis Murdoch, M.D.
Employees
30
Fiscal year end
12-31
Website
braveheart.bio

Company profile

Exchange
US
Symbol
BRVE
Market-cap rank
#2845
Listing date
2026-08-06
Market cap
1.67B
Float cap
348.38M
Shares out
90.04M
Float shares
18.75M

Sectors & themes

Biotechnology IPOs

Browse all sectors & themes

Quote time 2026-10-08 07:00:27 · For reference only, not investment advice and not tailored to your situation.